Ascendis Pharma A/S (NASDAQ:ASND) Coverage Initiated at Raymond James Financial

Stock analysts at Raymond James Financial initiated coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report issued to clients and investors on Friday, MarketBeat.com reports. The brokerage set a “strong-buy” rating and a $271.00 price target on the biotechnology company’s stock. Raymond James Financial’s price objective would suggest a potential upside of 28.74% from the company’s previous close.

ASND has been the subject of a number of other research reports. UBS Group reaffirmed a “buy” rating and set a $307.00 price objective (up previously from $306.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Citigroup reaffirmed a “buy” rating and set a $290.00 price target (up previously from $243.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Wall Street Zen downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, October 8th. Finally, Cantor Fitzgerald upped their price objective on Ascendis Pharma A/S from $203.00 to $254.00 and gave the stock an “overweight” rating in a report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $249.80.

Ascendis Pharma A/S Stock Up 1.7%

Shares of Ascendis Pharma A/S stock opened at $210.50 on Friday. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $216.45. The business’s fifty day moving average is $199.16 and its two-hundred day moving average is $177.64. The firm has a market cap of $12.99 billion, a PE ratio of -40.79 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.49. The business had revenue of $216.28 million during the quarter, compared to analysts’ expectations of $163.17 million. Equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Pursue Wealth Partners LLC purchased a new stake in Ascendis Pharma A/S during the 1st quarter worth $226,000. Diversified Trust Co lifted its stake in shares of Ascendis Pharma A/S by 3.4% during the first quarter. Diversified Trust Co now owns 46,548 shares of the biotechnology company’s stock worth $7,255,000 after purchasing an additional 1,510 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Ascendis Pharma A/S by 24.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 189,613 shares of the biotechnology company’s stock worth $28,713,000 after buying an additional 36,875 shares during the period. New Wave Wealth Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S in the first quarter valued at about $222,000. Finally, GF Fund Management CO. LTD. raised its holdings in shares of Ascendis Pharma A/S by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,544 shares of the biotechnology company’s stock valued at $241,000 after buying an additional 278 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.